Related Experiment Video
Updated: Aug 19, 2025

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
Silencing P2X7R Alleviates Diabetic Neuropathic Pain Involving TRPV1 via PKCε/P38MAPK/NF-κB Signaling Pathway in Rats
Lisha Chen1, Hongji Wang1, Juping Xing1
1Department of Physiology, Basic Medical College of Nanchang University, Nanchang 330006, China.
Abstract:
Transient receptor potential vanillic acid 1 (TRPV1) is an ion channel activated by heat and inflammatory factors involved in the development of various types of pain. The P2X7 receptor is in the P2X family and is associated with pain mediated by satellite glial cells. There might be some connection between the P2X7 receptor and TRPV1 in neuropathic pain in diabetic rats. A type 2 diabetic neuropathic pain rat model was induced using high glucose and high-fat diet for 4 weeks and low-dose streptozocin (35 mg/kg) intraperitoneal injection to destroy islet B cells. Male Sprague Dawley rats were administrated by intrathecal injection of P2X7 shRNA and p38 inhibitor, and we recorded abnormal mechanical and thermal pain and nociceptive hyperalgesia. One week later, the dorsal root ganglia from the L4-L6 segment of the spinal cord were harvested for subsequent experiments. We measured pro-inflammatory cytokines, examined the relationship between TRPV1 on neurons and P2X7 receptor on satellite glial cells by measuring protein and transcription levels of P2X7 receptor and TRPV1, and measured protein expression in the PKCε/P38 MAPK/NF-κB signaling pathway after intrathecal injection. P2X7 shRNA and p38 inhibitor relieved hyperalgesia in diabetic neuropathic pain rats and modulated inflammatory factors in vivo. P2X7 shRNA and P38 inhibitors significantly reduced TRPV1 expression by downregulating the PKCε/P38 MAPK/NF-κB signaling pathway and inflammatory factors in dorsal root ganglia. Intrathecal injection of P2X7 shRNA alleviates nociceptive reactions in rats with diabetic neuropathic pain involving TRPV1 via PKCε/P38 MAPK/NF-κB signaling pathway.
Insights
Targeting the P2X7 receptor and p38 signaling pathway alleviates neuropathic pain in diabetic rats. This intervention reduces TRPV1 expression and inflammatory factors, offering a potential therapeutic strategy for diabetic pain.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Transient receptor potential vanilloid 1 (TRPV1) and P2X7 receptors are implicated in pain signaling.
- Diabetic neuropathic pain involves complex inflammatory pathways and ion channel interactions.
Purpose of the Study:
- To investigate the potential link between P2X7 receptor and TRPV1 in diabetic neuropathic pain.
- To evaluate the therapeutic effects of P2X7 shRNA and p38 inhibitor on pain and inflammation in a rat model.
Main Methods:
- A type 2 diabetic neuropathic pain rat model was established.
- Rats received intrathecal injections of P2X7 shRNA or a p38 inhibitor.
- Dorsal root ganglia were analyzed for protein and gene expression, including inflammatory cytokines and signaling pathways (PKCε/P38 MAPK/NF-κB).
Main Results:
- Both P2X7 shRNA and p38 inhibitor treatment significantly reduced hyperalgesia and modulated inflammatory factors.
- TRPV1 expression was significantly decreased by these treatments.
- The PKCε/P38 MAPK/NF-κB signaling pathway and inflammatory factors in dorsal root ganglia were downregulated.
Conclusions:
- P2X7 receptor inhibition alleviates nociceptive responses in diabetic neuropathic pain.
- The mechanism involves the downregulation of TRPV1 expression via the PKCε/P38 MAPK/NF-κB signaling pathway.
- Targeting P2X7 and p38 pathways presents a promising therapeutic approach for diabetic neuropathic pain.

